EP4010078A4 - COMPOSITIONS AND METHODS FOR ENHANCING OPIOID RECEPTOR MOBILIZATION BY OPIOID HEXADENOATES AND OPTIONALLY SUBSTITUTED HEXADIENATES - Google Patents
COMPOSITIONS AND METHODS FOR ENHANCING OPIOID RECEPTOR MOBILIZATION BY OPIOID HEXADENOATES AND OPTIONALLY SUBSTITUTED HEXADIENATES Download PDFInfo
- Publication number
- EP4010078A4 EP4010078A4 EP20852037.9A EP20852037A EP4010078A4 EP 4010078 A4 EP4010078 A4 EP 4010078A4 EP 20852037 A EP20852037 A EP 20852037A EP 4010078 A4 EP4010078 A4 EP 4010078A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hexadienoates
- opioid
- compositions
- methods
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WSWCOQWTEOXDQX-UHFFFAOYSA-N 2,4-Hexadienoic acid Chemical class CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 title 2
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885311P | 2019-08-11 | 2019-08-11 | |
| US16/540,058 US11186585B2 (en) | 2018-08-17 | 2019-08-14 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| PCT/US2020/021599 WO2021029914A1 (en) | 2019-08-11 | 2020-03-07 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4010078A1 EP4010078A1 (en) | 2022-06-15 |
| EP4010078A4 true EP4010078A4 (en) | 2023-08-09 |
Family
ID=74571142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20852037.9A Pending EP4010078A4 (en) | 2019-08-11 | 2020-03-07 | COMPOSITIONS AND METHODS FOR ENHANCING OPIOID RECEPTOR MOBILIZATION BY OPIOID HEXADENOATES AND OPTIONALLY SUBSTITUTED HEXADIENATES |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4010078A4 (https=) |
| JP (1) | JP7535569B2 (https=) |
| CN (1) | CN114828961B (https=) |
| CA (1) | CA3149152A1 (https=) |
| MX (1) | MX2022001520A (https=) |
| WO (1) | WO2021029914A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0615756A1 (en) * | 1993-03-15 | 1994-09-21 | National Science Council | Nalbuphine esters and long-acting pharmaceutical compositions containing them |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668685A (en) | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| CN1050130C (zh) | 1997-07-04 | 2000-03-08 | 卢正堂 | 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法 |
| DE60001487T2 (de) | 2000-04-27 | 2003-12-24 | Oliver Yoa-Pu Hu | Polynalbuphinderivat |
| TWI226239B (en) | 2000-05-15 | 2005-01-11 | You-Pu Hu | Novel oral pharmaceutical composition containing nalbuphine ester prodrug |
| EP1309354A2 (en) | 2000-07-27 | 2003-05-14 | Rutgers, The State University | Therapeutic polyesters and polyamides |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| WO2005009377A2 (en) | 2003-07-23 | 2005-02-03 | University Of Kentucky Research Foundation | Novel oral bioavailable prodrugs |
| US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
| US20090192095A1 (en) | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| BRPI1015108A2 (pt) | 2009-04-02 | 2016-04-26 | Shire Llc | pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos |
| WO2011007247A1 (en) | 2009-07-17 | 2011-01-20 | Llc Shire | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| MX2012000980A (es) | 2009-07-21 | 2012-06-12 | Nektar Therapeutics | Conjugados de agonistas de oligómeros-opioides. |
| US20110190267A1 (en) * | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
| US8461171B2 (en) | 2010-02-09 | 2013-06-11 | QRxPharma Ltd. | Hybrid opioid compounds and compositions |
| CA2795156C (en) * | 2010-04-02 | 2019-05-14 | Alltranz Inc. | Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| EP2658523A1 (en) | 2010-12-28 | 2013-11-06 | Euro-Celtique S.A. | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
| US10017519B2 (en) * | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
| CN107427509B (zh) * | 2015-08-29 | 2021-06-15 | 美德阿利克斯株式会社 | 含有碱性药物和山梨酸的经皮吸收组成物 |
| US12590065B2 (en) | 2017-04-14 | 2026-03-31 | Zevra Therapeutics, Inc. | Levorphanol prodrugs and processes for making and using them |
| US11186585B2 (en) * | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
-
2020
- 2020-03-07 CA CA3149152A patent/CA3149152A1/en active Pending
- 2020-03-07 JP JP2022509137A patent/JP7535569B2/ja active Active
- 2020-03-07 EP EP20852037.9A patent/EP4010078A4/en active Pending
- 2020-03-07 WO PCT/US2020/021599 patent/WO2021029914A1/en not_active Ceased
- 2020-03-07 MX MX2022001520A patent/MX2022001520A/es unknown
- 2020-03-07 CN CN202080071185.9A patent/CN114828961B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0615756A1 (en) * | 1993-03-15 | 1994-09-21 | National Science Council | Nalbuphine esters and long-acting pharmaceutical compositions containing them |
Non-Patent Citations (1)
| Title |
|---|
| PENG, X. ET AL.: "Synthesis and Preliminary In vitro Investigation of Bivalent Ligands Containing Homo- and Heterodimeric Pharmacophores at [mu], [delta], and [kappa] Opioid Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 1, 2005, pages 256 - 262, XP055925192, ISSN: 0022-2623, DOI: 10.1021/jm050577x * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544564A (ja) | 2022-10-19 |
| WO2021029914A1 (en) | 2021-02-18 |
| CN114828961A (zh) | 2022-07-29 |
| MX2022001520A (es) | 2022-07-21 |
| CN114828961B (zh) | 2024-03-29 |
| CA3149152A1 (en) | 2021-02-18 |
| EP4010078A1 (en) | 2022-06-15 |
| JP7535569B2 (ja) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4054621A4 (en) | COMPOSITIONS AND METHODS FOR REPLACING RNA-ENCODED DNA ALLELES | |
| EP3490591A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING ADIPOSITAS BY INHIBITING FSH / FSHR | |
| GB201913701D0 (en) | Composition of matter | |
| IL290324A (en) | Preparations containing tropintide | |
| EP3609664B8 (en) | Asphalt compositions and methods of making same | |
| EP3952924A4 (en) | COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC PRODUCTS | |
| EP3876938A4 (en) | COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS | |
| EP3924509A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED CDNA SYNTHESIS | |
| CA3256071A1 (en) | A2-73 crystalline polymorph compositions of matter and methods of use thereof | |
| EP4028058A4 (en) | COMPOSITIONS AND METHODS FOR PRODUCING AND USING MULTISPECIFIC ANTIBODIES | |
| EP4010078A4 (en) | COMPOSITIONS AND METHODS FOR ENHANCING OPIOID RECEPTOR MOBILIZATION BY OPIOID HEXADENOATES AND OPTIONALLY SUBSTITUTED HEXADIENATES | |
| EP3328364A4 (en) | Novel dual delayed release oral composition of dexlansoprazole | |
| EP3994168A4 (en) | ANTIBODIES AGAINST LEPTIN RECEPTOR | |
| EP4077236A4 (en) | CEMENT ADDITIVE | |
| EP3344593A4 (en) | COMPOSITIONS AND METHODS OF WELL CEMENTING | |
| EP3277665A4 (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| HK40079201A (en) | Methods of producing antibody compositions | |
| HK40065908A (en) | Compositions of trofinetide | |
| HK40081744A (en) | Recombinase compositions and methods of use | |
| HK40075075A (en) | Recombinase compositions and methods of use | |
| HK40080649A (en) | Methods of using il-33 antagonists | |
| HK40045736A (en) | A2-73 crystalline polymorph compositions of matter and methods of use thereof | |
| HK40061383A (en) | Methods for making mixed allergen compositions | |
| HK40073249A (zh) | Crf受体拮抗剂及其使用方法 | |
| HK40070174A (en) | Hmgb1 antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220211 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0025360000 Ipc: C07C0219220000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230710 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/439 20060101ALI20230704BHEP Ipc: A61P 25/36 20060101ALI20230704BHEP Ipc: A61P 25/14 20060101ALI20230704BHEP Ipc: A61P 17/00 20060101ALI20230704BHEP Ipc: C07D 489/08 20060101ALI20230704BHEP Ipc: C07D 489/02 20060101ALI20230704BHEP Ipc: C07D 221/28 20060101ALI20230704BHEP Ipc: C07D 221/26 20060101ALI20230704BHEP Ipc: C07C 219/22 20060101AFI20230704BHEP |